Abstract

The specific objectives of this contract are to establish the validity of current documentation of observed early initial response to treatment of acute ischemic stroke with recombinant tissue plasminogen activator (rt-PA) and to establish time limits for delivering such treatment. The objectives will be accomplished by completing a Phase II-B randomized controlled clinical study of rt-PA for acute ischemic stroke.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research and Development Contracts (N01)
Project #
N01NS002374-011
Application #
2321153
Study Section
Project Start
1990-06-30
Project End
1995-10-31
Budget Start
1994-09-30
Budget End
1994-10-31
Support Year
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
University of Cincinnati
Department
Neurology
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221

  Publications

Rhoney, Denise H; Coplin, William M; Lin, Yan et al. (2010) Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience. J Stroke Cerebrovasc Dis 19:40-8
Nichols, Christopher; Khoury, Jane; Brott, Thomas et al. (2008) Intravenous recombinant tissue plasminogen activator improves arterial recanalization rates and reduces infarct volumes in patients with hyperdense artery sign on baseline computed tomography. J Stroke Cerebrovasc Dis 17:64-8
Jauch, Edward C; Lindsell, Christopher; Broderick, Joseph et al. (2006) Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37:2508-13
Tanne, David; Macko, Richard F; Lin, Yan et al. (2006) Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37:1798-804
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group (2005) Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 46:243-52
Kwiatkowski, Thomas; Libman, Richard; Tilley, Barbara C et al. (2005) The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med 45:377-84
Lu, Mei; Lyden, Patrick D; Brott, Thomas G et al. (2005) Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods 143:209-16
Hacke, Werner; Donnan, Geoffrey; Fieschi, Cesare et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-74
Tanne, D; Levine, S R; Brey, R L et al. (2003) Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology 61:1158-9
Bruno, A; Levine, S R; Frankel, M R et al. (2002) Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59:669-74

Showing the most recent 10 out of 33 publications